Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)
Completed
- Conditions
- Cerebral NecrosisNashopharyngeal CancerNerve Growth Factor
- Interventions
- Drug: NGF group
- Registration Number
- NCT02032147
- Lead Sponsor
- Fudan University
- Brief Summary
Cerebral radiation necrosis (CRN) is a well-documented late complication of radiation therapy for cancers, and may have a devastating effect on the patient's quality of life (QOL). However,CRN was once regarded as a progressive and irreversible disease, no standard therapy has been suggested for CRN. In our clinical practice, we have used nerve growth factor(NGF) to treat CRN, and found that GM1 can successfully reverse CRN. A case report has been published in Journal of Clinical Oncology (JCO) in 2011. So we carried out this prospective study to test the efficacy of NGF for CRN.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- The necrotic mass shown on MRI must be measured in two dimensions. No local or regional recurrence, no distant metastasis. Karnofsky performance status of at least 70 and were supposed to live more than 6 months.
Exclusion Criteria
- CRN combined with local or regional relapse, or with distant metastasis.
- CRN combined with other cerebrovascular disease.
- CRN combined with the second primary malignancy.
- CRN without neurologic symptoms or signs.
- CRN combined with diabetes.
- CRN patients that were supposed to live less than 6 months.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description NGF group NGF group This group will be treated with NGF 18u daily for 60 days.
- Primary Outcome Measures
Name Time Method efficacy of using NGF for treating CRN 6-8 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shanghai Cancer Center, Fudan University
🇨🇳Shanghai, Shanghai, China